Cargando…

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma

BACKGROUND: The treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now represent a challenge with inferior progression free survival (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335564/ https://www.ncbi.nlm.nih.gov/pubmed/34367987 http://dx.doi.org/10.3389/fonc.2021.703233

Ejemplares similares

PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
por: Sridhar, Amrutha, et al.
Publicado: (2023)

Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
por: Asher, Samir, et al.
Publicado: (2022)

OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines
por: Chan, Wei Yee, et al.
Publicado: (2021)

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
por: Chan, Wei Yee, et al.
Publicado: (2021)

The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study
por: Camilleri, Marquita, et al.
Publicado: (2022)

PB2108: SPINAL INVOLVEMENT IS ASSOCIATED WITH HIGH INCIDENCE OF SKELETAL RELATED EVENTS AND INFERIOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA. A SINGLE CENTRE EXPERIENCE IN 653 PATIENTS.
por: Kanellias, Nikolaos, et al.
Publicado: (2023)

Deferred autologous stem cell transplantation in systemic AL amyloidosis
por: Manwani, Richa, et al.
Publicado: (2018)

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design
por: Koutoukidis, Dimitrios A., et al.
Publicado: (2020)

A rare case of relapsed multiple myeloma with aberrant T‐cell antigen expression and skin plasmacytomas
por: Lecat, Catherine S.Y., et al.
Publicado: (2021)

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing
por: Malhotra, Karan, et al.
Publicado: (2016)

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS
por: Khwaja, J., et al.
Publicado: (2022)

Thoracic amyloidomas: Two case reports of an evasive diagnosis
por: Cresner, Rosie, et al.
Publicado: (2014)

Plasmablastic myeloma progressed to plasma cell leukaemia
por: Xu, Ke, et al.
Publicado: (2021)

Multiple myeloma and physical activity
por: Lecat, Catherine S. Y., et al.
Publicado: (2021)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
por: Carmichael, Jonathan, et al.
Publicado: (2023)

Lenalidomide‐induced eosinophilic pneumonia
por: Toma, Andrew, et al.
Publicado: (2017)

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy
por: Cook, Gordon, et al.
Publicado: (2020)

P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE
por: Mateos, M, et al.
Publicado: (2022)

P910: DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS
por: Khwaja, Jahanzaib, et al.
Publicado: (2023)

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response
por: Latifoltojar, Arash, et al.
Publicado: (2016)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
por: Leleu, X, et al.
Publicado: (2017)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
por: Dimopoulos, MA, et al.
Publicado: (2022)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
por: Tan, Carlyn, et al.
Publicado: (2023)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?
por: Tailor, Imran K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cecfldoltdkd8atrsngbakr3u0